{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:56:01Z","timestamp":1783691761032,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"PhD student tuition grant","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]},{"name":"PhD student tuition grant","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]},{"name":"NIH\/NCI Grants","award":["R43CA221389"],"award-info":[{"award-number":["R43CA221389"]}]},{"name":"NIH\/NCI Grants","award":["R43CA221389"],"award-info":[{"award-number":["R43CA221389"]}]},{"name":"Zhejiang Provincial Natural Science Foundation of China","award":["LQ23H300008"],"award-info":[{"award-number":["LQ23H300008"]}]},{"name":"National Key Research and Development Program of China","award":["2022YFC2804104"],"award-info":[{"award-number":["2022YFC2804104"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2022M712823"],"award-info":[{"award-number":["2022M712823"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001784","name":"Pancreatic Cancer Action Network","doi-asserted-by":"publisher","award":["24-CAT-LIFZ"],"award-info":[{"award-number":["24-CAT-LIFZ"]}],"id":[{"id":"10.13039\/100001784","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mesothelioma Applied Research Foundation Grant","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]},{"name":"Pancreatic Cancer Action Network (PanCAN) Translational Research Grant","award":["20-65-FENG"],"award-info":[{"award-number":["20-65-FENG"]}]},{"name":"donation funds from cancer patients and their family members","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Malignant pleural mesothelioma (MPM) responds poorly to chemotherapy and is a highly progressive malignancy with a median survival time of only 6\u20139 months. Therefore, the development of anti-MPM tumor agents with high efficacy and low toxicity is urgent and addresses an unmet need for MPM patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Medicinal chemistry synthesis of small molecules based on the FL118 drug platform were further comparatively investigated using multiple MPM and osteosarcoma cell\/tumor in vitro and\/or in vivo models. The method includes cell viability assay, Western blot analysis, colony formation assay, immunocytochemical staining, \u03b2-galactosidase senescence staining, flow cytometry, DNA fragmentation cell death detection, vector-free CRISPR-Cas9-mediated gene knockout, bioinformatic analysis, FL496 efficacy determination using severe combined immunodeficiency (SCID) mice with human MPM tumor, and immunohistochemistry (IHC) analysis of MPM tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Here, we report that we identified a novel FL118-derived small molecule (FL496). FL496 appears to be strikingly more effective in inhibiting MPM tumor growth in MPM tumor animal models than the currently most prevalent pemetrexed-cisplatin combination in the clinic. The treatment of MPM cells with FL496 rapidly induced p53 and p21 accumulation, and Rb and p-Rb inhibition, which were associated with MPM cell senescence and G\n                      <jats:sub>1<\/jats:sub>\n                      \/G\n                      <jats:sub>0<\/jats:sub>\n                      arrest and apoptosis. Knockout (KO) of the TP53\/p53 gene decreased the ability of FL496 to inhibit MPM cell growth (i.e., increase FL496 IC\n                      <jats:sub>50<\/jats:sub>\n                      values) and colony formation. FL496-treated MPM cells resulted in strong inhibition of the expression of survivin, Mcl-1, Bcl-2, Bcl-XL, and the induction of active caspase-3, cleaved PARP, and PUMA, which were further confirmed using MPM tumor tissues via IHC analysis. High survivin in MPM patients\u2019 tumors is associated with poor patient survival. Similar to FL118, FL496 treatment reduces DDX5 expression in MPM cells, but FL496 is more potent than FL118 in inhibiting MPM cell growth. Therefore, the mechanism of action (MOA) of FL496 overlaps with, but is likely beyond the scope of FL118 MOA, which needs further investigation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Together, these results indicate that FL496 is a promising anti-MPM small molecule, and its high anti-MPM potential is worthy of being further explored as a monotherapeutic agent to treat MPM patients in clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03547-9","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:45:29Z","timestamp":1761043529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["FL496, an FL118-derived small molecule, induces growth inhibition, senescence, and apoptosis of malignant pleural mesothelioma (MPM) cells, and exhibits anti-MPM tumor efficacy strikingly superior to the pemetrexed-cisplatin combination"],"prefix":"10.1186","volume":"44","author":[{"given":"Ieman A. M.","family":"Aljahdali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Stablewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Azrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengzhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"issue":"13","key":"3547_CR1","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMra1912719","volume":"385","author":"SM Janes","year":"2021","unstructured":"Janes SM, Alrifai D, Fennell DA. Perspectives on the treatment of malignant pleural mesothelioma. N Engl J Med. 2021;385(13):1207\u201318.","journal-title":"N Engl J Med"},{"issue":"11","key":"3547_CR2","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1097\/JTO.0b013e3181f1cf2b","volume":"5","author":"MT Milano","year":"2010","unstructured":"Milano MT, Zhang H. Malignant pleural mesothelioma: a population-based study of survival. J Thorac Oncol. 2010;5(11):1841\u20138.","journal-title":"J Thorac Oncol"},{"key":"3547_CR3","doi-asserted-by":"crossref","unstructured":"Kotecha R, Tonse R, Rubens M, Appel H, Albrecht F, Kaywin P et al. Meta-Analysis of survival and development of a prognostic nomogram for malignant pleural mesothelioma treated with systemic chemotherapy. Cancers (Basel). 2021;13(9).","DOI":"10.3390\/cancers13092186"},{"key":"3547_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1743-8977-7-5","volume":"7","author":"K Donaldson","year":"2010","unstructured":"Donaldson K, Murphy FA, Duffin R, Poland CA. Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma. Part Fibre Toxicol. 2010;7:5.","journal-title":"Part Fibre Toxicol"},{"issue":"8","key":"3547_CR5","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","volume":"17","author":"TA Yap","year":"2017","unstructured":"Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17(8):475\u201388.","journal-title":"Nat Rev Cancer"},{"key":"3547_CR6","doi-asserted-by":"crossref","unstructured":"Alay A, Cordero D, Hijazo-Pechero S, Aliagas E, Lopez-Doriga A, Marin R et al. Integrative transcriptome analysis of malignant pleural mesothelioma reveals a clinically relevant immune-based classification. J Immunother Cancer. 2021;9(2).","DOI":"10.1136\/jitc-2020-001601"},{"issue":"4","key":"3547_CR7","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48(4):407\u201316.","journal-title":"Nat Genet"},{"key":"3547_CR8","doi-asserted-by":"crossref","unstructured":"Quetel L, Meiller C, Assi\u00e9 JB, Blum Y, Imbeaud S, Montagne F et al. Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival. Mol Oncol. 2020.","DOI":"10.1002\/1878-0261.12651"},{"issue":"9","key":"3547_CR9","doi-asserted-by":"publisher","first-page":"e45571","DOI":"10.1371\/journal.pone.0045571","volume":"7","author":"X Ling","year":"2012","unstructured":"Ling X, Cao S, Cheng Q, Keefe JT, Rustum YM, Li FA, Novel Small. Molecule FL118 that selectively inhibits Survivin, Mcl-1, XIAP and cIAP2 in a p53-Independent Manner, shows superior antitumor activity. PLoS ONE. 2012;7(9):e45571.","journal-title":"PLoS ONE"},{"issue":"2","key":"3547_CR10","first-page":"139","volume":"5","author":"X Ling","year":"2013","unstructured":"Ling X, Li F. An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI). Am J Transl Res. 2013;5(2):139\u201354.","journal-title":"Am J Transl Res"},{"issue":"2","key":"3547_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1021\/mp4004282","volume":"11","author":"J Zhao","year":"2014","unstructured":"Zhao J, Ling X, Cao S, Liu X, Wan S, Jiang T, et al. Antitumor activity of FL118, a survivin, Mcl-1, XIAP, cIAP2 selective inhibitor, is highly dependent on its primary structure and steric configuration. Mol Pharm. 2014;11(2):457\u201367.","journal-title":"Mol Pharm"},{"issue":"10","key":"3547_CR12","first-page":"1765","volume":"7","author":"X Ling","year":"2015","unstructured":"Ling X, Liu XJ, Zhong K, Smith N, Prey J, Li F. FL118, a novel camptothecin analogue, overcomes Irinotecan and Topotecan resistance in human tumor xenograft models. Am J Transl Res. 2015;7(10):1765\u201381.","journal-title":"Am J Transl Res"},{"issue":"2","key":"3547_CR13","first-page":"370","volume":"7","author":"F Li","year":"2017","unstructured":"Li F, Ling X, Harris DL, Liao J, Wang Y, Westover D, et al. Topoisomerase I (Top1): a major target of FL118 for its antitumor efficacy or mainly involved in its side effects of hematopoietic toxicity? Am J Cancer Res. 2017;7(2):370\u201382.","journal-title":"Am J Cancer Res"},{"issue":"5","key":"3547_CR14","doi-asserted-by":"publisher","first-page":"e881","DOI":"10.1002\/ctm2.881","volume":"12","author":"X Ling","year":"2022","unstructured":"Ling X, Wu W, Aljahdali IAM, Liao J, Santha S, Fountzilas C, et al. FL118, acting as a \u2018molecular glue degrader\u2019, binds to, dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy. Clin Translational Med. 2022;12(5):e881.","journal-title":"Clin Translational Med"},{"issue":"2","key":"3547_CR15","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.3324\/haematol.2018.213314","volume":"105","author":"LC Holthof","year":"2020","unstructured":"Holthof LC, van der Horst HJ, van Hal-van Veen SE, Ruiter RWJ, Li F, Buijze M, et al. Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed\/refractory multiple myeloma. Haematologica. 2020;105(2):e80\u20133.","journal-title":"Haematologica"},{"issue":"5","key":"3547_CR16","doi-asserted-by":"publisher","first-page":"e561","DOI":"10.1097\/HS9.0000000000000561","volume":"5","author":"LC Holthof","year":"2021","unstructured":"Holthof LC, Stikvoort A, van der Horst HJ, Gelderloos AT, Poels R, Li F, et al. Bone marrow mesenchymal stromal Cell-mediated resistance in multiple myeloma against NK cells can be overcome by introduction of CD38-CAR or TRAIL-variant. Hemasphere. 2021;5(5):e561.","journal-title":"Hemasphere"},{"issue":"13","key":"3547_CR17","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1158\/1078-0432.CCR-20-2188","volume":"27","author":"LC Holthof","year":"2021","unstructured":"Holthof LC, van der Schans JJ, Katsarou A, Poels R, Gelderloos AT, Drent E, et al. Bone marrow mesenchymal stromal cells can render multiple myeloma cells resistant to cytotoxic machinery of CAR T cells through Inhibition of apoptosis. Clin Cancer Res. 2021;27(13):3793\u2013803.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3547_CR18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s13046-018-0899-8","volume":"37","author":"X Ling","year":"2018","unstructured":"Ling X, Wu W, Fan C, Xu C, Liao J, Rich LJ, et al. An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer. J Exp Clin Cancer Res. 2018;37(1):240.","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"3547_CR19","doi-asserted-by":"publisher","first-page":"101001","DOI":"10.1016\/j.jpha.2024.101001","volume":"14","author":"X Ling","year":"2024","unstructured":"Ling X, Wu W, Yan L, Curtin L, Farrauto MM, Sexton S, et al. Clinically and orally compatible formulation-manufactured DDX5 (p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancer. J Pharm Anal. 2024;14(11):101001.","journal-title":"J Pharm Anal"},{"issue":"24","key":"3547_CR20","doi-asserted-by":"publisher","first-page":"16888","DOI":"10.1021\/acs.jmedchem.3c01589","volume":"66","author":"W Wang","year":"2023","unstructured":"Wang W, Ling X, Wang R, Xiong H, Hu L, Yang Z, et al. Structure-Activity relationship of FL118 platform position 7 versus position 9-Derived compounds and their mechanism of action and antitumor activity. J Med Chem. 2023;66(24):16888\u2013916.","journal-title":"J Med Chem"},{"key":"3547_CR21","doi-asserted-by":"publisher","first-page":"117143","DOI":"10.1016\/j.ejmech.2024.117143","volume":"283","author":"W Wang","year":"2025","unstructured":"Wang W, Wang R, An L, Li L, Xiong H, Li D, et al. Design, synthesis and investigation of biological activity and mechanism of fluoroaryl-substituted derivatives at the FL118 position 7. Eur J Med Chem. 2025;283:117143.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"3547_CR22","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s13046-021-02026-1","volume":"40","author":"F Li","year":"2021","unstructured":"Li F, Aljahdali IAM, Zhang R, Nastiuk KL, Krolewski JJ, Ling X. Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1alpha, HIF2alpha, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma. J Exp Clin Cancer Res. 2021;40(1):254.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"3547_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJMoa1505917","volume":"374","author":"WM Linehan","year":"2016","unstructured":"Cancer Genome Atlas Research N, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, et al. Comprehensive molecular characterization of papillary Renal-Cell carcinoma. N Engl J Med. 2016;374(2):135\u201345.","journal-title":"N Engl J Med"},{"key":"3547_CR24","unstructured":"Ling X, Li QY, Li F. inventors; Zhejiang University of Technology, China, and Canget BioTekpharm, USA, assignee. Matter of composition, synthesis, formulation and application of FL118 platform positions 7 and 9-derived analogues for treatment of human disease (PCT\/US2019\/051595)2019 September 17, 2018."},{"issue":"1","key":"3547_CR25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1148\/radiol.12121021","volume":"267","author":"TK Nayak","year":"2013","unstructured":"Nayak TK, Bernardo M, Milenic DE, Choyke PL, Brechbiel MW. Orthotopic pleural mesothelioma in mice: SPECT\/CT and MR imaging with HER1- and HER2-targeted radiolabeled antibodies. Radiology. 2013;267(1):173\u201382.","journal-title":"Radiology"},{"key":"3547_CR26","doi-asserted-by":"crossref","unstructured":"Sudo H, Tsuji AB, Sugyo A, Kaneko MK, Kato Y, Nagatsu K et al. Preclinical evaluation of Podoplanin-Targeted Alpha-Radioimmunotherapy with the novel antibody NZ-16 for malignant mesothelioma. Cells. 2021;10(10).","DOI":"10.3390\/cells10102503"},{"key":"3547_CR27","doi-asserted-by":"publisher","first-page":"1508912","DOI":"10.3389\/fchem.2024.1508912","volume":"12","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Tian Y, Gao W, Hu Y, Luo L, Lei L, et al. Detection of PD-L1 expression levels in malignant pleural mesothelioma with a targeted MRI nanoprobe in vivo. Front Chem. 2024;12:1508912.","journal-title":"Front Chem"},{"issue":"4","key":"3547_CR28","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1158\/1078-0432.CCR-23-0873","volume":"30","author":"CR Schott","year":"2024","unstructured":"Schott CR, Koehne AL, Sayles LC, Young EP, Luck C, Yu K, et al. Osteosarcoma PDX-Derived cell line models for preclinical drug evaluation demonstrate metastasis Inhibition by Dinaciclib through a Genome-Targeted approach. Clin Cancer Res. 2024;30(4):849\u201364.","journal-title":"Clin Cancer Res"},{"key":"3547_CR29","doi-asserted-by":"crossref","unstructured":"Gaudreau-Lapierre A, Garneau D, Djerir B, Coulombe F, Morin T, Marechal A. Investigation of protein recruitment to DNA lesions using 405 Nm laser Micro-irradiation. J Visualized Experiments: JoVE. 2018(133):57410.","DOI":"10.3791\/57410"},{"key":"3547_CR30","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.lungcan.2005.03.037","volume":"49","author":"X Ling","year":"2005","unstructured":"Ling X, Yang J, Tan D, Ramnath N, Younis T, Bundy BN, et al. Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer. 2005;49:353\u201361.","journal-title":"Lung Cancer"},{"issue":"3","key":"3547_CR31","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1158\/1078-0432.982.11.3","volume":"11","author":"M Hazarika","year":"2005","unstructured":"Hazarika M, White RM Jr., Booth BP, Wang YC, Ham DY, Liang CY, et al. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res. 2005;11(3):982\u201392.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3547_CR32","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1158\/1078-0432.CCR-08-1579","volume":"15","author":"F Vandermeers","year":"2009","unstructured":"Vandermeers F, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny A, et al. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res. 2009;15(8):2818\u201328.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3547_CR33","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/ijc.27611","volume":"132","author":"K Iwahori","year":"2013","unstructured":"Iwahori K, Serada S, Fujimoto M, Ripley B, Nomura S, Mizuguchi H, et al. SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma. Int J Cancer. 2013;132(2):459\u201371.","journal-title":"Int J Cancer"},{"key":"3547_CR34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejps.2018.07.035","volume":"123","author":"F Sonvico","year":"2018","unstructured":"Sonvico F, Barbieri S, Colombo P, Barocelli E, Mucchino C, Cantoni AM, et al. Combined hyaluronate-based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: preliminary evaluation in an orthotopic tumor recurrence model. Eur J Pharm Sci. 2018;123:89\u201397.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"3547_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-016-2483-y","volume":"16","author":"Y Jiang","year":"2016","unstructured":"Jiang Y, Zhong B, Kawamura K, Morinaga T, Shingyoji M, Sekine I, et al. Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma. BMC Cancer. 2016;16(1):1\u201315.","journal-title":"BMC Cancer"},{"issue":"4","key":"3547_CR36","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/14737140.2021.1856660","volume":"21","author":"S Arulananda","year":"2021","unstructured":"Arulananda S, Lee EF, Fairlie WD, John T. The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma. Expert Rev Anticancer Ther. 2021;21(4):413\u201324.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"3547_CR37","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41420-021-00505-0","volume":"7","author":"S Arulananda","year":"2021","unstructured":"Arulananda S, O\u2019Brien M, Evangelista M, Jenkins LJ, Poh AR, Walkiewicz M, et al. A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. Cell Death Discov. 2021;7(1):122.","journal-title":"Cell Death Discov"},{"issue":"4","key":"3547_CR38","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1080\/02841860500468927","volume":"45","author":"SL O\u2019Kane","year":"2006","unstructured":"O\u2019Kane SL, Pound RJ, Campbell A, Chaudhuri N, Lind MJ, Cawkwell L. Expression of Bcl-2 family members in malignant pleural mesothelioma. Acta Oncol. 2006;45(4):449\u201353.","journal-title":"Acta Oncol"},{"issue":"9","key":"3547_CR39","first-page":"1996","volume":"6","author":"N Khodayari","year":"2016","unstructured":"Khodayari N, Mohammed KA, Lee H, Kaye F, Nasreen N. MicroRNA-302b targets Mcl-1 and inhibits cell proliferation and induces apoptosis in malignant pleural mesothelioma cells. Am J Cancer Res. 2016;6(9):1996\u20132009.","journal-title":"Am J Cancer Res"},{"issue":"4","key":"3547_CR40","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41419-021-03668-x","volume":"12","author":"D Xu","year":"2021","unstructured":"Xu D, Liang SQ, Yang Z, Yang H, Bruggmann R, Oberhaensli S, et al. Malignant pleural mesothelioma co-opts BCL-XL and autophagy to escape apoptosis. Cell Death Dis. 2021;12(4):406.","journal-title":"Cell Death Dis"},{"issue":"6","key":"3547_CR41","first-page":"453","volume":"29","author":"N Zaffaroni","year":"2007","unstructured":"Zaffaroni N, Costa A, Pennati M, De Marco C, Affini E, Madeo M, et al. Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell Oncol. 2007;29(6):453\u201366.","journal-title":"Cell Oncol"},{"issue":"1","key":"3547_CR42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00428-021-03031-7","volume":"478","author":"MB Beasley","year":"2021","unstructured":"Beasley MB, Galateau-Salle F, Dacic S. Pleural mesothelioma classification update. Virchows Arch. 2021;478(1):59\u201372.","journal-title":"Virchows Arch"},{"issue":"14","key":"3547_CR43","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636\u201344.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3547_CR44","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1634\/theoncologist.9-5-482","volume":"9","author":"M Hazarika","year":"2004","unstructured":"Hazarika M, White RM, Johnson JR, Pazdur R. FDA drug approval summaries: pemetrexed (Alimta). Oncologist. 2004;9(5):482\u20138.","journal-title":"Oncologist"},{"issue":"12","key":"3547_CR45","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.22.02542","volume":"41","author":"NJ Vogelzang","year":"2023","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2023;41(12):2125\u201333.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3547_CR46","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S2213-2600(24)00119-X","volume":"12","author":"E Lim","year":"2024","unstructured":"Lim E, Waller D, Lau K, Steele J, Pope A, Ali C, et al. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. Lancet Respir Med. 2024;12(6):457\u201366.","journal-title":"Lancet Respir Med"},{"issue":"11","key":"3547_CR47","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","volume":"27","author":"PM Forde","year":"2021","unstructured":"Forde PM, Anagnostou V, Sun Z, Dahlberg SE, Kindler HL, Niknafs N, et al. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and Immunologic analyses from the phase 2 PrE0505 trial. Nat Med. 2021;27(11):1910\u201320.","journal-title":"Nat Med"},{"issue":"24","key":"3547_CR48","doi-asserted-by":"publisher","first-page":"7487","DOI":"10.1158\/0008-5472.CAN-14-0683","volume":"74","author":"X Ling","year":"2014","unstructured":"Ling X, Xu C, Fan C, Zhong K, Li F, Wang X. FL118 induces p53-Dependent senescence in colorectal cancer cells by promoting degradation of MdmX. Cancer Res. 2014;74(24):7487\u201397.","journal-title":"Cancer Res"},{"issue":"1","key":"3547_CR49","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s13046-023-02787-x","volume":"42","author":"F Li","year":"2023","unstructured":"Li F, Ling X, Chakraborty S, Fountzilas C, Wang J, Jamroze A, et al. Role of the DEAD-box RNA helicase DDX5 (p68) in cancer DNA repair, immune suppression, cancer metabolic control, virus infection promotion, and human Microbiome (microbiota) negative influence. J Exp Clin Cancer Res. 2023;42(1):213.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"3547_CR50","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00428-013-1373-9","volume":"462","author":"J Hmeljak","year":"2013","unstructured":"Hmeljak J, Erculj N, Dolzan V, Pizem J, Kern I, Kovac V, et al. Is survivin expression prognostic or predictive in malignant pleural mesothelioma? Virchows Arch. 2013;462(3):315\u201321.","journal-title":"Virchows Arch"},{"issue":"6","key":"3547_CR51","first-page":"3871","volume":"19","author":"G Zhang","year":"2020","unstructured":"Zhang G, Yang DL, Zheng G, Liang Y. Survivin expression as an independent predictor of overall survival in malignant peritoneal mesothelioma. Oncol Lett. 2020;19(6):3871\u201380.","journal-title":"Oncol Lett"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03547-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03547-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03547-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:04:48Z","timestamp":1761087888000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03547-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3547"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03547-9","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Competing interests: FL118 and FL118 core structure-based analogues will be further developed in Canget BioTekpharma LLC (\n                      \n                      ), a Roswell Park Cancer Institute spinoff company. FL and XL are two of the initial eighteen investors of Canget to develop FL118 and FL118 core structure-relevant anticancer agents. FL is a full-time employee at Roswell Park Comprehensive Cancer Center (RPCCC) with an adjunct role acting as Chief Scientific Officer (CSO) in the Roswell Park spinoff Canget. FL has a conflict of interest (COI) management plan in place with Roswell Park.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FL118 and FL118 core structure-based analogues will be further developed in Canget BioTekpharma LLC (\n                      \n                      ), a Roswell Park Cancer Institute spinoff company. FL and XL are two of the initial eighteen investors of Canget to develop FL118 and FL118 core structure-relevant anticancer agents. FL is a full-time employee at Roswell Park Comprehensive Cancer Center (RPCCC) with an adjunct role acting as Chief Scientific Officer (CSO) in the Roswell Park spinoff Canget. FL has a conflict of interest (COI) management plan in place with Roswell Park.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests (This section should be deleted sine the above already has this Competing interests section)"}}],"article-number":"293"}}